secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001607062-21-000481
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen Biopharma awarded USPTO patent for NR2F6-silenced cord blood killer cell cancer therapy
--------------------------------------------------------------------------------

- USPTO issued Patent No. 11,141,471 on Oct 12, 2021, covering universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells.
- Invention targets NR2F6 silencing or gene editing in cord blood cells to produce potentiated killer cells for anticancer therapy.
- Patent includes compositions of matter, cells, and treatment protocols for inducing anticancer immune responses.
- Allogeneic cord blood killer cells are administered to initiate antitumor immune responses, first allogeneic then endogenous.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000481/0001607062-21-000481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000481/rgbp110321form8k.htm
  HTML page:      https://secwatch.observer/filing/0001607062-21-000481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer